首页 | 本学科首页   官方微博 | 高级检索  
检索        

Ezetimibe抑制胆固醇结石形成的实验研究
引用本文:王启晗,孙海东,蔡劬,胡海,韩天权,蒋兆彦.Ezetimibe抑制胆固醇结石形成的实验研究[J].外科理论与实践,2018,23(1):41-47.
作者姓名:王启晗  孙海东  蔡劬  胡海  韩天权  蒋兆彦
作者单位:1.上海交通大学医学院附属瑞金医院上海消化外科研究所,上海 200025;
2.同济大学附属东方医院胆石病中心 同济大学医学院胆石病研究所,上海 201200
摘    要:目的 探讨ezetimibe(Eze)对胆囊胆固醇结石形成的抑制作用。方法 将30只雄性成年C57BL/6小鼠随机分为普通饲料喂养(chow)组、成石饲料喂养(LD)组和成石饲料加Eze组Eze 5 mg/(kg·d)灌胃]。饲养8周后收集血清、肝脏、小肠和胆囊。观察胆囊内胆固醇结石形成情况。采用酶法测定血清、胆汁成分、肝组织胆固醇含量。采用实时定量PCR测定肝脏和小肠胆固醇代谢相关基因mRNA相对表达量。结果 chow组小鼠胆囊内未发现结石形成。LD组小鼠胆囊结石形成率为100%。Eze组完全无结石形成。Eze组小鼠小肠胆固醇吸收率(9.29%±4.32%),较LD组(58.62%±3.10%)和chow组(56.42%±2.67%)均显著降低(P<0.01)。LD组血清胆固醇(4.99±0.50) mmol/L]和肝组织胆固醇含量(22.92±2.39) mg/g]均较chow组(2.87±0.06) mmol/L和(2.45±0.08) mg/g]显著增加(P<0.05)。Eze组血清胆固醇(1.11±0.10) mmol/L]和肝组织胆固醇含量(2.70±0.07) mg/g]均较LD组显著降低(P<0.05)。LD组小鼠胆汁胆固醇含量LD组(10.87±1.46) mmol/L比chow组(3.67±0.58) mmol/L]和胆固醇饱和指数LD组(1.42±0.19)比chow组(0.59±0.02)]显著增加。Eze组胆汁胆固醇含量(2.72±0.29) mmol/L]和胆固醇饱和指数(0.57±0.07)均较LD组显著降低(P<0.01)。结论 Eze抑制小肠胆固醇肠道摄取,具有预防胆囊胆固醇结石形成的作用。

关 键 词:Ezetimibe  胆固醇结石病  小肠  
收稿时间:2017-05-08

Ezetimibe prevented cholesterol gallstone formation in mice fed with lithogenic diet
WANG Qihan,SUN Haidong,CAI Qu,HU Hai,HAN Tianquan,JIANG Zhaoyan.Ezetimibe prevented cholesterol gallstone formation in mice fed with lithogenic diet[J].Journal of Surgery Concepts & Practice,2018,23(1):41-47.
Authors:WANG Qihan  SUN Haidong  CAI Qu  HU Hai  HAN Tianquan  JIANG Zhaoyan
Institution:1. Shanghai Institute of Digestive Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China;
2. Center of Gallbladder Disease, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 201200, China
Abstract:Objective To investigate the effect of prevention on cholesterol gallstone formation by ezetimibe (Eze) in mice. Methods Thirty adult male C57BL/6 mice were randomly divided into three groups, fed with chow diet (chow group), lithogenic diet (LD group) and lithogenic diet with 5 mg/ (kg·d) ezetimibe by oral gavage (Eze group) for 8 weeks. On sacrifice, occurrence of gallstone was observed. Serum, liver, intestine and gallbladder were collected from each mouse. The serum lipids, hepatic cholesterol and biliary lipid composition were quantified by enzymatic methods. Expression of genes involved in metabolism of cholesterol in liver and intestines were measured by real-time quantitative PCR. Results No gallstone was observed in chow group. All mice formed gallstone in LD group (100%). No gallstone was formed in Eze group also. The intestinal cholesterol absorption rate in Eze group (9.29%±4.32%) significantly reduced when compared with LD group (58.62%±3.10%) and chow group (56.42%±2.67%) (P<0.01). Serum cholesterol level and hepatic cholesterol level in LD group (4.99±0.50) mmol/L and (22.92±2.39) mg/g] increased markedly compared with chow group (2.87±0.06) mmol/L and (2.45±0.08) mg/g] (P<0.05). Eze group lowered both serum cholesterol level (1.11±0.10) mmol/L] and hepatic cholesterol level (2.70±0.07) mg/g] compared with LD group(P<0.05). LD group has significantly higher biliary cholesterol content LD group (10.87±1.46) mmol/L vs chow group (3.67±0.58) mmol/L] and cholesterol saturation index (CSI) LD group:(1.42±0.19) vs chow group:(0.59±0.02)]. Biliary cholesterol content (2.72±0.29) mmol/L] and CSI (0.57±0.07) in Eze group decreased markedly compared with LD group (P<0.01). Conclusions Eze could prevent cholesterol gallstone formation in mice through inhibition of intestinal cholesterol absorption.
Keywords:Ezetimibe  Cholesterol gallstone disease  Intestine  
本文献已被 CNKI 等数据库收录!
点击此处可从《外科理论与实践》浏览原始摘要信息
点击此处可从《外科理论与实践》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号